VC-backed Histogenics goes public

By Iris Dorbian — 1 year ago

Waltham, Mass.-based Histogenics Corp., a regenerative medicine developer, has debuted its IPO after pricing its 5.9 million shares at $11 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “HSGX.” Cowen and Co., Needham & Co. and Canaccord Genuity are the lead underwriters. Histogenics’ backers include Sofinnova Ventures, Split Rock Partners and Altima Partners.

Continue

Deerfield leads $42.5 mln round for Audentes

By Iris Dorbian — 1 year ago

San Francisco-based biotech firm Audentes Therapeutics has secured $42.5 million in Series B financing. Deerfield Management led the round with participation from Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures. As a result of the transaction, Jonathan Leff, a partner at Deerfield, will join Audentes’ board of directors.

Continue

Sofinnova Ventures, OrbiMed, Vivo Capital lead $60 mln funding in Ascendis Pharma

By Chris Witkowsky — 1 year ago

Sofinnova Ventures, OrbiMed and Vivo Capital have led a $60 million Series D funding in Ascendis Pharma, a biotechnology company. Other investors in the funding include Janus Capital Management, Venrock, RA Capital Management, Rock Springs Capital and Sectoral Asset Management. Ascendis Pharma’s largest shareholder, Sofinnova Partners, also participated in the funding round. James Healy of Sofinnova Ventures, Jonathan Silverstein of OrbiMed and Albert Cha of Vivo Capital have joined the company’s board of directors.

Continue

Aclaris attracts $21 mln Series B

By Iris Dorbian — 1 year ago

Aclaris Therapeutics said Thursday that it has received $21 million in Series B financing. The investors were return backers Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Based in Malvern, Penn., Aclaris Therapeutics is a specialty pharmaceutical firm focused on developing a treatment that removes various skin lesions.

Continue

Civitas Therapeutics scores $55 mln Series C

By Iris Dorbian — 1 year ago

Civitas Therapeutics has closed $55 million in Series C funding. The investors included Adage Capital Management, OrbiMed Advisors, Partner Fund Management, Rock Springs Capital, Sofinnova Ventures, Canaan Partners, RA Capital and Wellington Management Company. Headquartered in Chelsea, Mass., Civitas Therapeutics is a biopharmaceutical company that focuses on developing treatments for Parkinson’s disease.

Continue

Big data analytics firm Guavus fetches $20 mln

By Iris Dorbian — 1 year ago

Guavus has received $20 million in funding. The investors included Artiman Ventures, Sofinnova Ventures, Intel Capital, SingTel Innov8, Investor Growth Capital, QuestMark Partners and Goldman Sachs. Based in San Mateo, Calif., Guavus is a provider of big data analytics solutions for operational intelligence.

Continue

VC-backed Sorbent Therapeutics expands board of directors

By Iris Dorbian — 2 years ago

Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has added Jay Shepard and William D. Waddill to its board of directors. Shepard is an executive partner at Sofinnova Ventures while Waddill is the senior vice president and chief financial officer at Calithera Biosciences. Sorbent’s backers include CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.

Continue

Teva agrees to buy VC-backed Labrys for up to $825 mln

By Iris Dorbian — 2 years ago

sraeli pharmaceutical company Teva Pharmaceutical Industries has agreed to acquire Labrys Biologics for $200 million in upfront payment in cash as well as up to $625 million in payments based on achievement of certain pre-launch milestones. Based in San Mateo, Calif., Labrys is a biotech firm focused on treating migraine. It was backed by venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures.

Continue

Spark Therapeutics attracts $72.8 mln Series B

By Iris Dorbian — 2 years ago

Spark Therapeutics has closed $72.8 million in Series B financing. Sofinnova Ventures led the round with participation from Brookside Capital, Deerfield Management Company, Rock Springs Capital, T. Rowe Price Associates, Wellington Management Company, The Children’s Hospital of Philadelphia and two unnamed healthcare funds. Based in Philadelphia, Spark Therapeutics is a developer of gene therapy products that treat rare, debilitating diseases.

Continue

Coherus BioSciences nabs $55 mln Series C

By Iris Dorbian — 2 years ago

Coherus BioSciences has raised $55 million in Series C funding. The investors included KKR, Venrock, RA Capital Management, Rock Springs Capital, Fidelity Biosciences, Sofinnova Ventures, Lilly Ventures and Vivo Capital. Based in Redwood City, Calif., Coherus BioSciences is a biologics platform focused on biosimilars.

Continue

Sorbent Therapeutics closes first tranche in $15 mln Series D

By Iris Dorbian — 2 years ago

Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has closed a $6.5 million tranche in a $15 million Series D financing. The investors were CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.

Continue

Principia Biopharma nabs $50 mln Series B funds

By Iris Dorbian — 2 years ago

Principia Biopharma has raised $50 million in Series B financing. Sofinnova Ventures led the round with participation from investors that include Morgenthaler Ventures, New Leaf Venture Partners, OrbiMed, SR One and Mission Bay Capital. In addition to the financing, Dr. Srinivas Akkaraju, a general partner at Sofinnova Ventures, has been added to Principia Biopharma’s board of directors. Based in South San Francisco, Principia Biopharma is focused on developing small molecule drugs within the fields of autoimmune disease and oncology.

Continue